1. Home
  2. EMO vs PHAT Comparison

EMO vs PHAT Comparison

Compare EMO & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ClearBridge Energy Midstream Opportunity Fund Inc.

EMO

ClearBridge Energy Midstream Opportunity Fund Inc.

HOLD

Current Price

$51.99

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$11.65

Market Cap

894.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EMO
PHAT
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
894.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
EMO
PHAT
Price
$51.99
$11.65
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$19.83
AVG Volume (30 Days)
51.9K
1.4M
Earning Date
01-01-0001
04-30-2026
Dividend Yield
6.70%
N/A
EPS Growth
N/A
42.72
EPS
N/A
N/A
Revenue
N/A
$175,110,000.00
Revenue This Year
N/A
$93.04
Revenue Next Year
N/A
$58.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
216.93
52 Week Low
$41.54
$3.92
52 Week High
$54.90
$18.31

Technical Indicators

Market Signals
Indicator
EMO
PHAT
Relative Strength Index (RSI) 57.35 45.67
Support Level $51.00 $11.04
Resistance Level $52.03 $13.08
Average True Range (ATR) 0.88 0.78
MACD 0.24 -0.12
Stochastic Oscillator 74.55 18.75

Price Performance

Historical Comparison
EMO
PHAT

About EMO ClearBridge Energy Midstream Opportunity Fund Inc.

ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions. The Fund considers investments in midstream entities as those entities that provide midstream services including the gathering, transporting, processing, fractionation, storing, refining, and distribution of oil, natural gas liquids and natural gas.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: